PlumX Metrics
Embed PlumX Metrics

30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma

Cancers, ISSN: 2072-6694, Vol: 15, Issue: 7
2023
  • 6
    Citations
  • 0
    Usage
  • 16
    Captures
  • 2
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Most Recent News

Data from University of Poitiers Broaden Understanding of Multiple Myeloma (30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma)

2023 APR 12 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Daily -- Data detailed on multiple myeloma have been presented. According to

Review Description

The treatment of multiple myeloma (MM) has greatly evolved these past few years. Recent advances in therapeutics have largely benefited elderly patients now renamed “non-transplant-eligible” (NTE) patients. Since the 1960s, and for several decades, chemotherapy was the only treatment for MM. Then, the field was marked by the emergence of targeted therapies in the 2000s, such as immunomodulating agents (thalidomide, lenalidomide, and pomalidomide) and proteasome inhibitors (bortezomib, carfilzomib, and ixazomib), which were the first steps towards an increase in survival. Thereafter, the apparition of monoclonal antibodies (mAbs) was considered a milestone in the treatment of MM for both transplant-eligible and NTE patients. Anti-CD38 mAbs can be safely administered to older patients with an impressive efficacy leading to a never-achieved-before survival rate with the triple association of anti-CD38 mAbs, lenalidomide, and dexamethasone. However, progress is still expected with the introduction in the armamentarium for NTE patients of the most recent innovative immunotherapy-based treatments newly introduced in MM, e.g., CAR-T cells and bispecific antibodies. These “improved versions” of immune-based treatments will probably also benefit NTE patients, although further studies will be needed to better understand their role in this population.

Bibliographic Details

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know